.png){kind=icon}
返回
R
Renate Pichler
Medical University of Innsbruck
31H指数
320论文数
3.9K被引数
收录论文 106
发表时间
.png){kind=icon}
Re: Can Aydogdu, Laura Bukavina, Liang Cheng, et al. Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.05.030阿多古杜等人. 尿路上皮癌的病理亚型及分化差异：病理学、基因组学和管理意义. 欧洲泌尿学杂志. 即将发表. https://doi.org/10.1016/j.eururo.2026.05.030.png)
European Urology.png)
European UrologyIF25.2
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)基线疾病特征和铂类药物敏感性作为顺铂为基础化疗、阿维鲁姆单抗维持治疗和恩沃利单抗维多汀序贯疗法在晚期尿路上皮癌中的预后预测因素（ARON-2EV研究）
PREAI
分享收藏
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221–34回复: Maria De Santis，Joan Palou Redorta，Hiroyuki Nishiyama等。Durvalumab联合BCG治疗初治、高危、非肌层浸润性膀胱癌 (POTOMAC): 一项随机、开放标签、3期试验的最终分析。柳叶刀2025;406:2221-34European Urology
European UrologyIF25.2
PREAI
分享收藏The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG): Analysis of USA insurance claim data免疫抑制状态对接受经尿道膀胱肿瘤切除术（TURBT）和辅助性膀胱内卡介苗（BCG）治疗的非肌层浸润性膀胱癌（NMIBCs）患者复发及无进展生存期的影响：美国医疗保险索赔数据分析
OAAI
OAAI分享收藏